



US008414921B2

(12) **United States Patent**  
**Kamali et al.**

(10) **Patent No.:** **US 8,414,921 B2**  
(45) **Date of Patent:** **Apr. 9, 2013**

(54) **PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH METFORMIN**

(75) Inventors: **Ashkan Kamali**, West Conshohocken, PA (US); **Laman Alani**, Lansdale, PA (US); **Kyle A. Fliszar**, Quakertown, PA (US); **Soumojeet Ghosh**, Lansdale, PA (US); **Monica Tijerina**, Doylestown, PA (US)

(73) Assignee: **Merck Sharp & Dohme Corp.**, Rahway, NJ (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/085,722**

(22) PCT Filed: **Dec. 12, 2006**

(86) PCT No.: **PCT/US2006/047380**

§ 371 (c)(1),  
(2), (4) Date: **May 29, 2008**

(87) PCT Pub. No.: **WO2007/078726**

PCT Pub. Date: **Jul. 12, 2007**

(65) **Prior Publication Data**

US 2009/0105265 A1 Apr. 23, 2009

#### Related U.S. Application Data

(60) Provisional application No. 60/750,954, filed on Dec. 16, 2005.

(51) **Int. Cl.**  
**A61K 9/20** (2006.01)

(52) **U.S. Cl.** ..... **424/465**

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

6,548,481 B1	4/2003	Demuth et al.	
2003/0139434 A1	7/2003	Balkan et al.	
2003/0166578 A1	9/2003	Arch et al.	
2004/0229848 A1	11/2004	Demuth et al.	
2004/0254167 A1	12/2004	Biftu et al.	
2005/0051922 A1 *	3/2005	Nangia et al.	424/464
2006/0210627 A1	9/2006	Pfeffer et al.	
2006/0270701 A1 *	11/2006	Kroth et al.	514/300
2006/0270722 A1 *	11/2006	Thornberry et al.	514/374
2007/0072810 A1 *	3/2007	Asakawa	514/19
2007/0172525 A1	7/2007	Sesha	
2008/0064701 A1	3/2008	Sesha	
2009/0253752 A1 *	10/2009	Burkey et al.	514/342
2009/0304790 A1 *	12/2009	Nilsson et al.	424/464

#### FOREIGN PATENT DOCUMENTS

CA	2 623 011 A1	4/2007
EP	1 557 165 A1	7/2005
JP	2003-520226 A	7/2003
JP	2003-535898 A	12/2003
JP	2005/041885 A	2/2005
JP	2005-514377 A	5/2005
WO	99/38501 A2	8/1999
WO	99/38501 A3	8/1999
WO	01/52825 A2	7/2001
WO	01/52825 A3	7/2001
WO	01/97808 A1	12/2001
WO	03/004498 A1	1/2003
WO	03/045977 A2	6/2003
WO	03/045977 A3	6/2003
WO	2004/028521 A1	4/2004
WO	2004/050022 A2	6/2004
WO	2004/050022 A3	6/2004
WO	2004/058266 A1	7/2004
WO	2005/013957 A2	2/2005
WO	2005/013957 A3	2/2005
WO	2005/041923 A1	5/2005
WO	2005/047297 A1	5/2005
WO	2005/082348 A2	9/2005
WO	2005/082849 A1	9/2005
WO	2006/047248 A1	5/2006
WO	2006/135723 A2	12/2006
WO	2006/135723 A3	12/2006
WO	2007/019255 A2	2/2007
WO	2007/019255 A3	2/2007
WO	2007/041053 A2	4/2007
WO	2007/041053 A3	4/2007

#### OTHER PUBLICATIONS

"Sitagliptin (MK-0431) for Type 2 Diabetes shows promise in Phase II clinical trials" from Medical News Today, Jun. 11, 2005, p. 1-3 (<http://www.medicalnewstoday.com/releases/25962.php>).

Ahren, B., et al., "Improved Meal-Related B-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1 Year", Diabetes Care, 2005, p. 1936-, vol. 28, No. 8.

Brazg, R. et al., "Effect of Adding MK-0431 to On-Going Metformin Therapy in Type 2 Diabetic Patients Who Have Inadequate Glycemic Control on Metformin", Diabetes, 2005, p. A3, vol. 54, Suppl 1.

Goldstein, B. J. et al., "Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes", Diabetes Care, 2007, p. 1979-, vol. 30, No. 8.

Herman, G. et al., "Co-Administration of MK-0431 and Metformin in Patients with Type 2 Diabetes Does Not Alter the Pharmacokinetics of MK-0431 or Metformin", p. A505.

\* cited by examiner

Primary Examiner — Bethany Barham

(74) Attorney, Agent, or Firm — Baerbel R. Brown; John C. Todaro

(57) **ABSTRACT**

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

**28 Claims, No Drawings**